Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market: Innovations in Non-invasive Treatment Alternatives to Provide Strong Impetus: Global Industry Analysis 2013-2017 and Opportunity Assessment 2018-2028

Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market: Innovations in Non-invasive Treatment Alternatives to Provide Strong Impetus: Global Industry Analysis 2013-2017 and Opportunity Assessment 2018-2028

Prevalence of Benign Prostatic Hyperplasia Is on a Steady Rise

According to the recent statistical data,

  • In the US, more than 8 million men are suffering from benign prostatic hyperplasia.
  • Globally, around 22 million men have been diagnosed with moderate-to-severe symptoms of benign prostatic hyperplasia.
  • The risk of having benign prostatic hyperplasia increases after the age of 40 by around 8%, and by the age of 90, the risk increases by as much as 60%.

The rising prevalence of benign prostatic hyperplasia (BPH) is the key factor driving the growth of the benign prostatic hyperplasia prostate treatment market. A few other factors such as diet, heredity, and lifestyle also play an important role in causing benign prostatic hyperplasia.

With the increasingly aging population and a changing demographic profile in almost all societies, it is expected that benign prostatic hyperplasia prostate treatment will become a major challenge for all healthcare systems, and even more prevalent among men during the forecast period.

Nearly 50% men across the world by the age of 50 years and above are suffering from the medical condition – benign prostatic hyperplasia (BPH) prostate, according to a study published in the Canadian Journal of Urology.

Stakeholders in the benign prostatic hyperplasia prostate treatment market are aiming to bolster their research & development activities to improve the efficacy of the existing medications. Thereby, the global market for benign prostatic hyperplasia prostate treatment is expected to witness steady growth, reaching US$ 25 billion in the coming decade.

Preeminent factors that are influencing the growth of the benign prostatic hyperplasia prostate treatment market include:

Advancements in Management of Benign Prostatic Hyperplasia

In the future, the demand for benign prostatic hyperplasia prostate treatment is expected to witness strong growth. Currently, a number of novel techniques are under clinical trials. Technology has played an important role in the latest advances in the management of benign prostatic hyperplasia prostate treatment.

Recently, a prostatic urethral lift has been considered to be one of the most favorable new techniques that have been performed in benign prostatic hyperplasia prostate treatment. In this technique, a novel mechanical implant is placed into the prostate by pulling the encroaching lobes of the prostate and improves a man’s urine flow.

Alpha-blockers are the first-line treatment that relaxes the prostate smooth muscle fibers. Excluding traditional oral solid dosage pharmaceuticals, many studies have been carried out using injectable drug delivery systems directly into the prostate. This has been stimulated by the increased use and efficiency of Botox treatment in the bladder. These initial trials of intraprostatic injections are expected to hold a promising influence on the overall development of benign prostatic hyperplasia prostate treatment market.

Mounting Costs of Benign Prostatic Hyperplasia Treatment

Financing healthcare costs due to the rising demand for benign prostatic hyperplasia prostate treatment is a great challenge. Basically, benign prostatic hyperplasia prostate treatment depends upon the severity of the condition and may involve pharmacotherapy and a number of surgical procedures. Hence, benign prostatic hyperplasia prostate treatment costs may vary dramatically. The latest UroLift System treatment is similar in effectiveness but costs twice as much as compared to other prostatic hyperplasia prostate treatments.

Economical and minimally invasive therapies are available options to patients, and are slightly more expensive than the combination of drug therapy and generic drugs. In the US, a few years ago, annual direct and indirect costs to the private sector associated with benign prostatic hyperplasia treatment were estimated to be US$ 4 Bn.

It has been observed that the costs tend to spike with the increasing number of aging men who are suffering from benign prostatic hyperplasia. High price point associated with the benign prostatic hyperplasia prostate treatment will continue to limit market growth in the long run.

Competition Analysis

The competitive landscape of benign prostatic hyperplasia prostate treatment market involves some of the industry behemoths, posing strong competition facing other smaller players. The report covers Pfizer, Inc., Valeant Pharmaceuticals Inc., Novartis AG, Bayer AG, Sanofi S.A., GlaxoSmithKline plc., Bristol-Myers Squibb and Company, Teva Pharmaceutical Industries Ltd, Mylan N.V., Merck & Co., Cardinal Health Inc., and Eli Lilly and Company among others.  

Definition

Benign prostatic hyperplasia prostate treatment includes a wide range of drugs and devices used for benign prostatic hyperplasia conditions. Drug-based therapy is the first line of treatment used widely for benign prostatic hyperplasia prostate treatment.

About the Report

The company conducted a research study on the benign prostatic hyperplasia prostate treatment market for the forecast period 2018 to 2028. This report provides a thorough assessment of opportunities in the benign prostatic hyperplasia prostate treatment market and provides an understanding of benign prostatic hyperplasia conditions, and lower urinary tract infections, and awareness level of benign prostatic hyperplasia prostate treatment and market competition in the benign prostatic hyperplasia prostate treatment market. The report provides thorough information regarding macroeconomic factors affecting the growth of the benign prostatic hyperplasia prostate treatment market.

Additional Questions Answered

Additional questions addressed in this benign prostatic hyperplasia prostate treatment market report are:

  • What is the revenue potential of the benign prostatic hyperplasia prostate treatment market across North America and Europe?
  • Who are the key players and what are their product portfolios in the benign prostatic hyperplasia prostate treatment market?
  • What are the major challenges impacting the growth of the benign prostatic hyperplasia prostate treatment market?
  • How is the involvement from key regulatory bodies shaping the growth of the benign prostatic hyperplasia prostate treatment market?

Research Methodology

The benign prostatic hyperplasia prostate treatment market has been estimated based on a supply-demand approach. The benign prostatic hyperplasia prostate treatment market was first studied based on the prevalence of benign prostatic hyperplasia conditions, diagnosis and treatment rate and availability of the drug in the different distribution channels across different regions/countries.

Further, qualitative factors impacting the benign prostatic hyperplasia prostate treatment market, such as awareness regarding benign prostatic hyperplasia prostate treatment and availability of drugs, average prices of drugs, key regulations and others, were studied.

Data analysis was validated through primary research methods, such as telephonic interviews, in-person interactions, surveys and viewpoints of experienced analysts & secondary research resources, such as trade journals, databases and verified paid sources. The research study on the benign prostatic hyperplasia prostate treatment market also provides the top trends and macro- and microeconomic factors influencing the benign prostatic hyperplasia prostate treatment market.

Key Segment

Based on treatment type

  • alpha-blockers
  • alpha reductase inhibitors
  • phosphodiesterase-5 (PDE-5) Inhibitors
  • muscarinic receptor antagonist
  • combination drugs

Based on distribution channel

  • institutional sales
  • retail sales
  • online pharmacies

Need specific information?

In the news

How Businesses Can Utilize Market Research to Create Reactive, Recession-proof Strategies for Survival

by - Sudip Saha, Managing Director and Co-Founder of Future Market Insights

Our Clients

View Our Reports from Healthcare

View Reports

Recommendations

Benign Prostatic Hyperplasia Bph And Prostate Treatment Market